The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | Flotetuzumab as salvage therapy for primary induction failure and early AML
Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA, discusses updated results of the first-in-human study of flotetuzumab, an investigational CD123 x CD3 bi-specific product currently in development for patients with acute myeloid leukemia (AML). Flotetuzumab has demonstrated encouraging activity in patients with primary induction failure and early relapse AML, which represents a population with poor prognosis and unmet need. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
